Good afternoon, ladies and gentlemen, and welcome to Masimo's First Quarter 2017 Earnings Conference Call. The company's press release is available at www.masimo.com. At this time, all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. I am pleased to introduce Eli Kammerman, Masimo's Vice President of Business Development and Investor Relations. Please go ahead.

Hello, everyone. Joining me today are Chairman and CEO, Joe Kiani and Executive Vice President of Finance and CFO, Mark de Raad. This call will contain forward-looking statements which reflect Masimo's current judgment, including certain of our expectations regarding fiscal 2017 financial performance. However, they are subject to risks and uncertainties that could cause actual results to differ materially. Risk factors that could cause our actual results to differ materially from our projections and forecasts are discussed in detail in our SEC filings, including our most recent Form 10-K and Form 10-Q. You will find these in the investor section of our website. I'll now pass the call to Joe Kiani.

Thank you, Eli. Good afternoon, and thank you for joining us for Masimo's 2017 first quarter review. Today, we are reporting product revenue results that illustrate the strength in our solutions that are helping care providers improve their care and reduce their cost. Our Q1 product revenue exceeded our expectations. As is evident from these results, we continue to successfully win new customers, not only due to our SET pulse oximetry and rainbow Pulse CO-Oximetry technology platforms, but also due to our expanding new products including Root, our new patient monitoring and connectivity hub. Our Q1 product revenues grew to $178.1 million, a 9% increase. We shipped 47,900 oximeters in Q1, producing a new estimated installed base of 1.525 million oximeters, excluding our SET handheld and finger pulse oximeters. Our Q1 2017 GAAP earnings per diluted share were $0.82, up from $0.53 in the same prior-year period. The Q1 2017 earnings per diluted share including a net benefit of $0.25 due to stock option exercises versus $0.02 in the prior-year quarter. In just a moment, Mark will provide you with a more detailed description of our quarterly financial results. I will be brief in my comments today, given that we will be hosting our Investor Day next week on Tuesday May 9, at our California headquarters. The goal of next week's meeting is to provide you with a broad overview on various topics regarding Masimo's outlook and vision for the next chapter after the completion of our 10-year post-IPO plan in 2017. The day will include demonstrations and discussions about our products, our business as well as some directional insight into our long-term financial goals. I hope you have already registered and if not, please do so at the investor events section of our website. Now, I will ask Mark to review in more detail our Q1 results and to provide you with a refinement on some of our original 2017 financial guidance. Mark?

Thank you, Joe, and good afternoon everybody. Our Q1 product revenues rose to $178.1 million or up 9.1%, or 9.5%, a difference of approximately $700,000 on a constant currency basis, versus the $163.3 million posted for the first quarter of 2016. The strength was attributable to strength in demand for our core technologies in U.S. and OUS markets as well as contributions from some of our new products including Root. As a remainder, we had expected our first quarter total revenue and rainbow revenue year-over-year comparisons to be more difficult due to the impact of the large $8.1 million total revenue order from a Saudi customer last year. As expected, due to the continuing financial constraint in Saudi Arabia, in the most recent quarter we generated $2.8 million from the same Saudi customer. Still despite this $5.3 million year-over-year decline, the fact that our product revenues were approximately $6 million higher than we expected and up 9.1% was very encouraging. We believe that part of this Q1 product revenue strength was due to the relatively severe flu season. Our Q1 total revenues which include royalty revenues were $186.3 million, up 8.8% from $171.2 million in the prior-year period. It's noteworthy to mention that this increase occurred despite not being able to recognize approximately $4 million in deferred revenue related to our Philips integration activities in Q1. While we were not able to recognize this additional revenue in Q1, we do expect to be able to do so in our second fiscal quarter and our estimate for this revenue has actually increased slightly to $4.4 million. rainbow product revenues for Q1 totaled $13.9 million, which was down by 17.8% from $16.9 million in the prior-year period. The decline in rainbow sales was due entirely to a decline of $4.2 million in…

Thank you, Mark. We have begun 2017 with a better than expected first quarter result. Given the partnership with Philips, the new studies on SpHb and PVi, the next generation rainbow SpHb performance and some of the new rainbow parameters including ORi, we are more confident about the potential for rainbow, particularly SpHb and PVi to become a standard of care in hospitals and we are diligently working towards educating clinicians about the benefits of using these measurements to achieve improved outcomes and reduced cost of care. On a related note, a recent study conducted at College at York Teaching Hospital in York, United Kingdom evaluated the performance of Masimo PVi monitoring in guiding fluid management, as compared to that of an established technology, esophageal Doppler. The researchers measured the absolute volume of fluid given intraoperatively and fluid volume at 24 hours and found no significant difference between PVi and esophageal Doppler groups in mean total fluid administered or mean intraoperative fluid balance. Therefore, they concluded that PVi offers a non-invasive consumable free alternative for intraoperative fluid optimization in fit patients undergoing major colorectal surgery, where intraoperative goal-directed therapy is deemed a standard of care, but there is no requirement for arterial cannulation. With that, our call today is somewhat briefer than unusual because we are planning to share much more detail about our business with everyone in six days, next Tuesday, May 9, when we hold our Investor Day in Irvine for the first time. We will be sharing an overview of our outlook for the next phase of our company including long range technology, product, sales, manufacturing, and financial direction for the next seven-year period. In closing, we once again, exceeded our projections with our Q1 financial results giving us confidence about our performance for the remainder of 2017. We've remained committed to our mission to improve patient outcomes and reduce the cost of care. We hope to see you next week in Irvine. With that, we'll open the call to questions. Operator?

And our first question comes from Tao Levy from Wedbush. Your line is now open.

Great. Thanks. Good afternoon, everyone.

Good afternoon.

Hi, Tao.

Maybe just, if you can talk about the first quarter and the flu season and any guesstimates as to what type of contribution that might have had on the business and now historically, we've always thought of it as impacting just to pull socks, but is there – could have, have a positively impacted other parts of them over the product portfolio?

Well, the flu season in Q1, Tao, was probably the second highest in the last several years, but that tailwind was offset somewhat by the headwind that we heard off from hospitals seeing a lower senses for elective surgeries. So we think while, certainly, it helped because without it maybe Q1 would have been a strong. We are not anticipating a big change going forward for the next three quarters.

Got it. And so as we think about the next few quarters and the way my model is built, I try to back into revenues per install, is there sort of like some sort of discount fact that we should apply to the first quarter because of flu, so that we don't over increase the remaining quarters?

Well, yes, and no. Broadly speaking, yes, because we believe overall procedures will be less in Q2 and Q3. However, there are international opportunities that sometimes come and go and sometimes balloon like last year did this for us in Q1 and who knows it could balloon for us in Q2 this year. So I think, normally, I would say, yes, I would say maybe couple percent lower on sensor consumption would be the right thing, but I think it might get offset by other opportunities around the world, in Middle East and Latin America. And also we've been doing really well with our new products like Root, like MightySat, and Radius-7 and so forth. So we feel that, while maybe there will be obviously less procedures normally in places like the U.S., we think it should be offset by what we end up doing around the world and in some of the new capital areas.

Got you. Very helpful. And just lastly for Mark, because you didn't collect some of that, the R&D revenues from Philips in Q1, does that also mean there wasn't sort of like an R&D expense and both of those events will now be in the second, take place in the second quarter?

Tao, yes. Tao, what is occurring is we're incurring these engineering expenses related to these deliverables. And so when we recognize the revenue like we will next quarter, what will happen is we'll take some of those engineering expenses and reclassify them from operating expenses up into the cost of sales section of the P&L.

Okay. Thank you very much.

Right. Thank you.

Thank you, Tao.

And our next question comes from Bill Quirk from Piper Jaffray. Your line is now open. William R. Quirk - Piper Jaffray & Co.: Great, thanks. Good afternoon, everybody.

Hi, Bill. How are you doing?

Hi, Bill. William R. Quirk - Piper Jaffray & Co.: Very well. So I apologize if you talked about this in your prepared comments. I did unfortunately have to jump on a few minutes late. But can you just maybe help talk us through some of the partnership with Philips and maybe some examples of how the two companies are working together to try to better integrate Masimo into some of their patient monitoring technologies?

Sure, sure. First of all the partnership is going very well at all levels of the organization. I've had calls with and meetings with the CEO of Philips a few times since we entered into our agreement. The teams are working collectively to launch our co-marketing campaigns as well as new products with our technology from rainbow to some of the new measurements like SedLine brain function monitoring, Nomoline capnography and gas monitoring and O3 organ oximetry or regional oximetry technologies. We are kicking things off officially in the next couple of weeks and we expect to get some benefit showing up in the second half, if not sooner. I think the goodwill that's been generated from this relationship is already translating itself into healthier growth. I think we had projected normally 7% growth annually. Because of Philips, we increased it to 8%. And I think we reported over 9% in Q1. And certainly, Philips is playing a part in that. So we're pretty excited. I think you're going to start seeing some announcements. Certainly next week when we meet for the Analyst Day, we'll talk more about it and give you some examples, more specific examples of what's to come. William R. Quirk - Piper Jaffray & Co.: Very good. Thanks, guys. Nice quarter.

Thank you, Bill.

Thanks, Bill.

And our next question comes from Larry Keusch from Raymond James. Your line is now open. Lawrence Keusch - Raymond James & Associates, Inc.: Great. Good afternoon, everyone.

Hi, Larry.

Hi, Larry. Lawrence Keusch - Raymond James & Associates, Inc.: Hello. So listen, just a couple quick questions for you guys. First off, could you talk a little bit about the cash balance? So if I understood it correctly, Mark, what you essentially said was in April, there was this $70 million-ish payment that would presumably reduce the reported cash balance that you talked about. Is that correct?

That's correct. Lawrence Keusch - Raymond James & Associates, Inc.: Okay, perfect. And then the bigger picture question is now with this cash on the balance sheet, which is still very healthy, what are the thoughts on the uses for that cash is, as you look forward here?

Well, who knows what future truly holds, but right now we're expecting to use our cash and maybe even some borrowing for acquisitions in the future. We've recently brought on board, Thierry Leclercq, who was for 30 years at GE, most recently running their patient monitoring business to head up business development for us. For those who are coming in next week, you'll meet him. So we – as we look forward to kind of the next seven years, we not only expect to grow organically in the range that Mark has been forecasting, but hopefully adding on to that growth from new acquisitions. Lawrence Keusch - Raymond James & Associates, Inc.: And what about thoughts around share repurchase? I actually don't think, if my memory is correct, you haven't repurchase any stock since the second quarter of 2016. But where does that priority fit in, when you compare it to M&A?

Well, I think it really depends. If we find the right companies with the right future that we think will help us get a much better return on acquiring them versus buying our own shares we'll do that. If we don't, which I hope we will, but if we don't then obviously buying back our own shares is probably the next best thing. Lawrence Keusch - Raymond James & Associates, Inc.: Okay. Terrific. And then last question, just can you remind us again the expected timing for a readout on the NACHO trial?

Good question. We're going to give you an update next week, but my understanding is that the enrollment is complete, and they're doing their analysis. So we hope they'll complete that in the next couple of months and they'll submit their manuscript for publication in the next few months. Lawrence Keusch - Raymond James & Associates, Inc.: Okay, terrific. Thanks guys. See you next week.

Thank you.

Thanks, Larry.

Thank you so much. Looks like you guys are as brief as we are today given the anticipated Analyst Day next week. We really appreciate you joining us. This marks our 28th anniversary, May 2 was the 28th anniversary of our incorporation in California. So we're excited and look forward to seeing you all and hopefully the weather will be great. So thank you so much. Have a wonderful day.

Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program. And you may all disconnect. Everyone have a great day.